Response Evaluation Criteria in Cancer of the Liver

Known as: RECICL 
Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 revised version). (Kudo M, Kubo… (More)
National Institutes of Health

Related topics

Related topics

1 relation
Clinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version).
The Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
Response evaluation criteria in cancer of the liver (RECICL 2015 revised version)
 
Is this relevant?
2015
2015
Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis.
OBJECTIVES Sorafenib has become a standard therapy for advanced hepatocellular carcinoma following the demonstration of… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2014
2014
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
BackgroundTo test the hypothesis that use of the response evaluation criteria in cancer of the liver (RECICL), an improved… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2014
2014
Pilot study of stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
BACKGROUND/AIMS We retrospectively evaluated the local tumor control and safety of transcatheter arterial chemoembolization (TACE… (More)
Is this relevant?
2014
2014
Efficacy of transarterial chemoembolization targeting portal vein tumor thrombus in patients with hepatocellular carcinoma.
AIM We aimed to retrospectively examine the tolerability and efficacy of transarterial chemoembolization (TACE) in patients with… (More)
  • figure 1
  • table II
  • table I
  • table III
  • figure 2
Is this relevant?
2013
2013
Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
AIM To evaluate the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) using miriplatin emulsion in… (More)
Is this relevant?
2013
2013
DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study
BACKGROUND/AIMS To determine if hepatocellular carcinoma refractory to conventional transarterial chemoembolization (TACE… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2012
2012
Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?
PURPOSE In order to detect an early response to anti-angiogenic therapy, this study aims at analyzing specific effects of a… (More)
Is this relevant?
2010
2010
Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version).
The World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST) are inappropriate to… (More)
  • table 2
Is this relevant?